Range of qualified patients: CDEC talked over the uncertainty in the quantity of individuals with reasonably serious to intense hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific professionals consulted by CADTH indicated that some people who are labeled as having gentle or reasonable sickness may have a severe bleeding pheno